<DOC>
	<DOCNO>NCT00771615</DOCNO>
	<brief_summary>The purpose observer-blind study determine whether GSK 's avian flu vaccine GSK 1557484A immunogenic give adult age 18-64 year .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety GSK 's Avian Flu Vaccine 1557484A Given Adults Aged 18-64 Years</brief_title>
	<detailed_description>All enrolled subject receive 1 dose study vaccine . All subject attend formal study center visit safety immunogenicity assessment Days 0 , 10 , 42 , 84 , 182 telephone safety contact Day 364 . This Protocol Posting update accord Protocol amendment , 8 Dec 08</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult 18 64 year age time first vaccination , inclusive . Written inform consent obtain subject . Stable health status define absence health event satisfy definition SAE , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within 1 month prior enrollment . Access consistent mean telephone contact , may either home workplace , land line , mobile , NOT pay phone multipleuser device . Comprehension study requirement , express availability require study period , ability attend schedule visit . Subjects investigator believe comply requirement protocol . Presence evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer , within 3 year . Presence oral temperature &gt; = 37.8ºC , acute symptom great `` mild '' severity schedule date vaccination . Any confirm suspected immunosuppressive immunodeficiency condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid ( prednisone &gt; = 10 mg/day 14 consecutive day ) within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration vaccine within 30 day first study vaccine dose . Previous administration H5N1 vaccine . Use investigational nonregistered product ( drug vaccine ) plan participation another investigational study within 30 day prior study enrollment , 12 month follow test article administration . Use investigational nonregistered product immunosuppressive property exclusionary time trial . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior vaccination . Lactating nursing . Women child bear potential ( lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior vaccination . Known receipt analgesic antipyretic medication specific intent prophylaxis vaccine reactogenicity day vaccination . Subjects stable chronic regimen potentially analgesic antipyretic medication preexist diagnosis require discontinue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>human</keyword>
	<keyword>Avian</keyword>
	<keyword>safety</keyword>
	<keyword>vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>pandemic</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>H5N1</keyword>
</DOC>